Cannabis and Psychosis: What the Numbers Actually Show

Few arguments turn up in the cannabis debate as reliably as this one: “Cannabis causes psychosis, so obviously the stuff is harmful.” The sentence sounds final. It isn’t. The research on cannabis and psychosis paints a far more precise picture, one that neither plays down the risk nor lumps every kind of use together. We went through the current evidence and worked out what it actually says.

Cannabis and psychosis: a link nobody seriously disputes

Let’s start with what holds up. There is a connection between cannabis use and psychosis, and it is well documented. People who use regularly have, on average, a higher risk of developing a psychotic disorder or schizophrenia than people who never use. That is not a fringe position; it runs through dozens of studies and reviews.

But the slogan “cannabis causes psychosis” glosses over the crucial point: how much, how potent and who account for almost the whole difference. That is where it gets interesting, and that is exactly where the blanket harm argument falls apart.

How high the risk actually is

Before talking about risk factors, it pays to look at the baseline, because without it, talk of “five times the risk” means nothing. The lifetime risk of developing schizophrenia in the general population sits at roughly 0.6 to 1%. Counting all psychotic disorders together (which includes delusional, schizoaffective and substance-induced forms) it rises to around 3%. Isolated, temporary psychosis-like experiences, without any illness being present, are something an estimated 5 to 7% of people have had at some point.

That single percentage point is the anchor for everything that follows. When a study reports a “doubled” or “fivefold” risk, it almost always means relative risk, measured against this baseline. A fivefold risk sounds like 50%, but starting from 1% it works out to roughly 5%. Keeping that difference between relative and absolute risk in mind gets you halfway to an honest debate.

The risk map: where cannabis actually sits

With that baseline in hand, you can put the whole list of known risk factors in order, and you see immediately that cannabis is not at the top of it. The overview below pulls together what meta-analyses report in terms of relative risk increase, along with a rough absolute reference point.

Factor Risk (relative) Absolute lifetime risk (approx.)
General population (baseline) n/a ~1% (schizophrenia), ~3% (all psychoses)
Identical twin affected n/a ~40–50%
Both parents affected n/a ~40%
Parent or sibling affected ~6x ~6–10%
Racism and discrimination ~4x ~4%
Childhood trauma (multiple, 5+ adversities) ~3x (up to ~6x) ~3–6%
Urban birth or urban upbringing ~2–3x ~2–3%
Cannabis: daily and high-potency ~5x ~3–5%
Cannabis: frequent use (weekly or more) ~1.3–2x ~2%
Migration or minority status ~2x ~2%

The absolute figures are rough reference points based on a baseline risk of around 1%. The factors do not simply add up; some of them interact or overlap. Relative risks for discrimination and childhood trauma follow the 2021 Frontiers in Psychiatry umbrella review and Varese et al. (2012).

Two things stand out. First, predisposition dominates everything else. Heritability estimates run from 60 to 80%, with a Danish twin cohort landing at around 79%, and an affected identical twin lifts the risk into an order of magnitude that no single environmental condition reaches (Hilker et al., 2018). Second, cannabis lands in the middle of the environmental factors: the daily high-potency extreme case is on a par with discrimination and childhood trauma, while ordinary use sits below that.

Then there is the population-level view, which flips the public weighting. For society, what counts is not only how strongly a factor acts but how widespread it is. Adverse childhood experiences are common, which is why an estimated third of all psychosis cases can be attributed to them statistically, more than to any other single factor (Varese et al., 2012). That is precisely why social adversity, trauma and discrimination often sit at the top of the list in prevention research, even though genetics carries the most weight in any individual case. On this map cannabis is one factor among several: real, moderate in size, and unlike genes, background or childhood, one of the few you can influence directly through your own behaviour.

Where the risk starts to rise

In 2022, a Canadian meta-analysis pulled together the evidence on how the frequency of use affects psychosis risk, across ten studies covering around 7,400 people (Robinson et al., 2022). The result is remarkably clear and rarely quoted, because it is hard to turn into a scandal.

People who use only occasionally, yearly or monthly, show no statistically significant increase in risk. Only from weekly use onwards does it climb measurably, by around a third. At daily use it then sits at roughly double that of non-users. So there is a threshold below which the data do not show an elevated risk. That is the first nuance the slogan loses: the relevant question is not “use, yes or no” but “how often”.

Potency is the real crux

The second nuance matters at least as much, and it explains why the debate looks different today than it did thirty years ago. That THC potency has risen steadily is well documented (Hoch et al., 2024). The figures usually cited: in the 1980s, THC content in cannabis was typically 2 to 4%, while today flower in legal markets often reaches 20% and more, and concentrates 80 to 90%. It is no longer the same substance.

A British longitudinal study tackled exactly this question (Hines et al., 2024). It followed adolescents over years and asked whether high-potency cannabis in adolescence is linked to psychotic experiences later on. The result: those who used high-potency cannabis as teenagers had roughly double the risk of new-onset psychotic experiences. For “any” cannabis use, by contrast, the association was weak and statistically uncertain.

That is the decisive finding. The effect hangs on potency, not on use as such. An even more recent analysis from the European research network EU-GEI marks the upper end of what current studies report: people who used high-potency cannabis daily had an approximately fivefold increased risk of developing a psychosis (Austin-Zimmerman et al., 2024). Fivefold, but for the combination of daily and high-potency, not for occasional, low-potency use.

“But surely it’s just the predisposition”

At this point the objection from the other side arrives just as reliably: the association isn’t really causal at all. People with a genetic predisposition to psychosis are simply more likely to reach for cannabis, so use is a symptom rather than a cause. That is a serious hypothesis, and the research has taken it seriously.

The same EU-GEI analysis calculated participants’ genetic schizophrenia load, a kind of genetic risk score built from hundreds of genetic variants. The researchers then checked whether the cannabis effect would survive once that predisposition was factored out. It did. The strong association between daily high-potency use and psychosis held up after accounting for genetic load. The study found no evidence that use and predisposition amplify one another, though it notes it may have been too small to detect such an interaction.

That weakens the convenient “it’s all just genetics” argument considerably, although the evidence from Mendelian randomisation studies remains mixed. Based on what we know today, cannabis does not look merely like a marker for a predisposition that was there anyway, but like a factor in its own right that adds real risk in susceptible people. Specialists call this a component cause: not the sole trigger, but a real one, and one you can act on.

The legalisation signal, read properly

Probably the most misused data point of recent years comes from Canada. An analysis from Ontario covering 13.6 million people found that after legalisation, the share of schizophrenia cases attributable to a cannabis use disorder rose from around 4 to 10%, and among young men aged 19 to 24 to almost 19% (Myran et al., 2025). That sounds like an alarm bell, and cannabis critics use it exactly that way.

Except that the same paper contains a second sentence which is almost never quoted alongside it: the absolute number of new schizophrenia diagnoses stayed stable across the entire period. There was no jump after legalisation. Put together, the two findings give a more nuanced picture. The “attributable share” is a relative measure; it can rise while the actual rate of illness does not move, for instance because problematic use is recognised and documented more often after legalisation.

The honest reading is therefore not “legalisation triggers a wave of psychosis” but this: the cannabis-linked share shifts, and it concentrates in a clearly identifiable group, young men with heavy use. That is an argument for targeted prevention, not for blanket panic.

Cannabis is not the only cause

One last piece of the puzzle keeps things grounded. Another EU-GEI study looked at why psychoses occur more frequently in some regions than in others (Brink et al., 2024). For the first time it accounted for two factors at once: how widespread daily cannabis use is in a region, and how pronounced social disadvantage is there, measured for example by home ownership rates.

The result: both factors contributed independently of one another, and deprivation did not disappear once use was accounted for. That makes cannabis one factor among several in a wider social context, not the one big lever that explains everything. Anyone who pins the psychosis story on the substance alone ignores that poverty, isolation and living conditions also shape the outcome.

What this means for the debate

Put the studies together and a picture emerges that fits neither the playing-down nor the demonising camp. Yes, there is a real risk. No, it does not apply equally to every kind of use. The danger concentrates in an identifiable combination: frequent, high-potency, young, and it intensifies when a family history or difficult living circumstances are added on top.

That precision is exactly what the blanket harm argument lacks. It shows that the risk is not diffuse, it is locatable, which means you can understand it and reduce it deliberately. For infrequent, low-potency use in adults, the studies show no statistically significant increase in psychosis risk. That is not the same as proof of no risk, and it says nothing about other risks such as dependence, nor about the developing brain in adolescence. If you use high-potency products daily and you are young, you are clearly in the risk zone. That is not a grey area of opinion; it is a fairly clear map.

If you want an informed approach, whether in a cannabis social club, in counselling or just in your own head, this gives you more to work with than any slogan: education about potency and frequency, particular protection for young people, and the honesty to treat cannabis as what it is, a substance with real but definable risks. That is exactly the difference between fearmongering and objectivity.

Key takeaways

  • For context: the baseline risk is ~1% (schizophrenia) and ~3% (all psychoses). A “fivefold risk” therefore means roughly 5%, not 50%. Relative is not absolute.
  • Predisposition dominates the risk map (heritability 60 to 80%); cannabis sits in the middle of the pack among environmental factors, alongside discrimination, childhood trauma and growing up in a city.
  • The link between cannabis and psychosis is real and well documented, but it hangs almost entirely on frequency and potency.
  • Below weekly use the data show no statistically significant increase in risk; daily use roughly doubles it.
  • High-potency cannabis is the actual driver. Daily plus high-potency means a roughly fivefold risk.
  • The effect persists once genetic predisposition is factored out: cannabis is a component cause, not merely a marker.
  • The Canadian legalisation signal is often overstated. The attributable share rose, the absolute rate of illness stayed stable.
  • Social factors such as disadvantage weigh at least as heavily. Cannabis is one factor among several, and one of the few you can influence.

Sources

Studies and analyses, with DOIs for cross-checking:

On baseline risk and risk factors:

  • Perälä et al. (2007), Archives of General Psychiatry, lifetime prevalence of psychotic disorders (~3%) · doi:10.1001/archpsyc.64.1.19
  • National Institute of Mental Health (NIMH), schizophrenia statistics (lifetime prevalence) · nimh.nih.gov/health/statistics/schizophrenia
  • Umbrella review (2021), Frontiers in Psychiatry, trauma, social adversity and discrimination as psychosis risks · doi:10.3389/fpsyt.2021.665957
  • Varese et al. (2012), Schizophrenia Bulletin, childhood adversity and psychosis risk (meta-analysis, PAF ~33%) · doi:10.1093/schbul/sbs050
  • Vassos et al. (2012), Schizophrenia Bulletin, meta-analysis on urbanicity and schizophrenia · doi:10.1093/schbul/sbs096
  • Hilker et al. (2018), Biological Psychiatry, heritability of schizophrenia from a Danish twin cohort (~79%) · doi:10.1016/j.biopsych.2017.08.017

Note: This article is written for adults. It puts the state of research in context and does not replace individual advice. Cannabis and mental health is a sensitive topic. If you are worried about yourself or someone close to you, medical and psychological services can help.

Spread the word!

This will close in 0 seconds

This will close in 0 seconds

Scroll to Top